Table 1. Modified intention-to-treat effectiveness of bismuth-based quadruple therapy in treatment-naïve and rescue patients in Europe.
| Schemes | Line of therapy | All lines | ||
| Naïve | Second-line | Rescue | ||
| ScBQT | ||||
| Cure rate (%) | 93.2 | 89.5 | 85.9 | 91.8 |
| n | 4477 | 1148 | 623 | 6248 |
| 95% CI | 92 to 94 | 88 to 91 | 83 to 89 | 91 to 93 |
| NScBQT schemes | ||||
| PPI+CAB | ||||
| Cure rate | 91.4 | 87.8 | 77.1 | 91.1 |
| n | 3826 | 181 | 35 | 4042 |
| 95% CI | 91 to 92 | 82 to 92 | 59 to 89 | 90 to 2 |
| PPI-MTB | ||||
| Cure rate (%) | 90.9 | 84.7 | 73.2 | 84.7 |
| n | 318 | 288 | 190 | 796 |
| 95% CI | 87 to 94 | 80 to 89 | 66 to 79 | 82 to 87 |
| PPI+MAB | ||||
| Cure rate (%) | 90.2 | 79.4 | 85 | 88.6 |
| n | 245 | 34 | 20 | 299 |
| 95% CI | 86 to 94 | 62 to 91 | 61 to 96 | 84 to 92 |
| PPI+LAB | ||||
| Cure rate (%) | 88.8 | 88.1 | 75.9 | 86 |
| n | 98 | 662 | 158 | 918 |
| 95% CI | 80 to 94 | 85 to 90 | 68 to 82 | 84 to 88 |
| PPI+JAB | ||||
| Cure rate (%) | 86.4 | 93.5 | 0 | 86,7 |
| n | 477 | 31 | 1 | 509 |
| 95% CI | 83 to 89 | 77 to 99 | 11 to 95 | 83 to 90 |
| PPI+TAB | ||||
| Cure rate (%) | 84.6 | 72.7 | 66.7 | 81.9 |
| n | 91 | 22 | 3 | 116 |
| 95% CI | 75 to 91 | 50 to 88 | 13 to 98 | 73 to 88 |
| PPI+MDB | ||||
| Cure rate (%) | 77 | 76.3 | 62.5 | 69.2 |
| n | 61 | 38 | 112 | 211 |
| 95% CI | 64 to 86 | 59 to 88 | 53 to 71 | 62 to 75 |
| Overall | ||||
| Cure rate (%) | 91.4 | 87.8 | 78.3 | 89.5 |
| n | 9955 | 2550 | 1262 | 13 767 |
| 95% CI | 91 to 92 | 87 to 89 | 76 to 81 | 89 to 90 |
Rescue: third-line therapy and beyond.
Treatment schemes with 90% or more effectiveness are marked in bold.
A, amoxicillin; B, bismuth salts; C, clarithromycin; D, doxycycline; J, josamycin; L, levofloxacin; M, metronidazole; NScBQT, non-single-capsule bismuth quadruple therapy; PPI, proton pump inhibitor; T, tetracycline